Literature DB >> 7927337

DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.

S Panserat1, C Mura, N Gérard, M Vincent-Viry, M M Galteau, E Jacqz-Aigrain, R Krishnamoorthy.   

Abstract

The molecular basis for DNA haplotype-dependent debrisoquine 4-hydroxylase (CYP2D6) expression was explored by sequencing all of the nine exons of the CYP2D6 gene. Two distinct exon sequence frameworks of the CYP2D6 gene were found, each associated with specific BamHI-defined DNA haplotypes of the CYP2D cluster. They corresponded to Arg296/Cys296 and Ser486/Thr486 amino acid polymorphisms in the CYP2D6 enzyme, and occurred in almost equal frequency among the Caucasians examined. These two major allozymes with amino acid differences in the presumed substrate recognition region and in the vicinity of the heme binding site could be the source of the observed DNA haplotype-dependent variation in phenotypic expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927337     DOI: 10.1007/bf00201601

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  29 in total

1.  Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.

Authors:  A K Daly; M Armstrong; S C Monkman; M E Idle; J R Idle
Journal:  Pharmacogenetics       Date:  1991-10

2.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.

Authors:  O Gotoh
Journal:  J Biol Chem       Date:  1992-01-05       Impact factor: 5.157

3.  High-resolution crystal structure of cytochrome P450cam.

Authors:  T L Poulos; B C Finzel; A J Howard
Journal:  J Mol Biol       Date:  1987-06-05       Impact factor: 5.469

4.  A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction.

Authors:  M Armstrong; J R Idle; A K Daly
Journal:  Hum Genet       Date:  1993-07       Impact factor: 4.132

5.  The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450.

Authors:  T L Poulos; B C Finzel; I C Gunsalus; G C Wagner; J Kraut
Journal:  J Biol Chem       Date:  1985-12-25       Impact factor: 5.157

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.

Authors:  S L Wang; J D Huang; M D Lai; B H Liu; M L Lai
Journal:  Clin Pharmacol Ther       Date:  1993-04       Impact factor: 6.875

8.  Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

Authors:  F J Gonzalez; F Vilbois; J P Hardwick; O W McBride; D W Nebert; H V Gelboin; U A Meyer
Journal:  Genomics       Date:  1988-02       Impact factor: 5.736

9.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.

Authors:  R Ayesh; J R Idle; J C Ritchie; M J Crothers; M R Hetzel
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

10.  A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease.

Authors:  Y Tsuneoka; Y Matsuo; K Iwahashi; H Takeuchi; Y Ichikawa
Journal:  J Biochem       Date:  1993-08       Impact factor: 3.387

View more
  8 in total

1.  CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.

Authors:  S Panserat; L Sica; N Gérard; H Mathieu; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 2.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

3.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.

Authors:  Chiaki Kawanishi; Stefan Lundgren; Hans Agren; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-02       Impact factor: 2.953

4.  Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6.

Authors:  Tohru Ohnuma; Nobuto Shibata; Yoichiro Matsubara; Heii Arai
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 5.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.

Authors:  S Panserat; C Mura; N Gérard; M Vincent-Viry; M M Galteau; E Jacoz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

7.  Pharmacogenetic testing revisited: 5' nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19.

Authors:  Jens Borggaard Larsen; Jan Borg Rasmussen
Journal:  Pharmgenomics Pers Med       Date:  2017-04-18

8.  CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort.

Authors:  Concetta Dagostino; Massimo Allegri; Valerio Napolioni; Simona D'Agnelli; Elena Bignami; Antonio Mutti; Ron Hn van Schaik
Journal:  Pharmgenomics Pers Med       Date:  2018-10-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.